Callie Coombs/LinkedIn
Jun 14, 2025, 07:12
Callie Coombs Discusses Updated CLL13 Data and Therapy Duration Implications for Clinical Practice
Callie Coombs, Associate clinical professor at University of California, Irvine, posted on X:
“CLL13 longer follow up – huge study and great presentation. Though GIV is superior, I would not use as SOC since the duration of therapy is longer (range 12-36 months) than ven/obi which is still quite excellent (and always 1 yr). And yes MRD still matters!”
More posts featuring EHA 2025.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 6, 2025, 20:34
Sep 6, 2025, 20:20
Sep 6, 2025, 20:00
Sep 6, 2025, 19:13
Sep 6, 2025, 19:01
Sep 6, 2025, 18:05
Sep 6, 2025, 17:52
Sep 6, 2025, 17:48